Today Sandoz filed IPR2018-00002, directed to AbbVie’s U.S. Patent No. 9,512,216. According to the petition, the ’216 patent claims a subcutaneously-administered dosing regimen for the anti-TNF-α antibody adalimumab, the active ingredient in AbbVie’s Humira ® product, to treat moderate to severe chronic plaque psoriasis. This is the second petition Sandoz filed on this same patent. According to Sandoz, the earlier petition, filed in July 2017, relies on a different combination of prior art. Both petitions are pending.
Sandoz has additional IPR petitions pending on other AbbVie patents as well. You can find more information on our IPR Tracker page.
The post SANDOZ FILES PETITION FOR IPR ON ABBVIE ADALIMUMAB PATENT appeared first on Goodwin Procter BioSimilars Blog.